These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 17517901)

  • 21. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
    Takezawa K; Okamoto I; Yonesaka K; Hatashita E; Yamada Y; Fukuoka M; Nakagawa K
    Cancer Res; 2009 Aug; 69(16):6515-21. PubMed ID: 19638574
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
    Adnane L; Trail PA; Taylor I; Wilhelm SM
    Methods Enzymol; 2006; 407():597-612. PubMed ID: 16757355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular modeling, dynamics simulations, and binding efficiency of berberine derivatives: A new group of RAF inhibitors for cancer treatment.
    Jabbarzadeh Kaboli P; Ismail P; Ling KH
    PLoS One; 2018; 13(3):e0193941. PubMed ID: 29565994
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elastin peptides activate extracellular signal-regulated kinase 1/2 via a Ras-independent mechanism requiring both p110gamma/Raf-1 and protein kinase A/B-Raf signaling in human skin fibroblasts.
    Duca L; Lambert E; Debret R; Rothhut B; Blanchevoye C; Delacoux F; Hornebeck W; Martiny L; Debelle L
    Mol Pharmacol; 2005 Apr; 67(4):1315-24. PubMed ID: 15653554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
    Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
    Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia.
    Zebisch A; Staber PB; Delavar A; Bodner C; Hiden K; Fischereder K; Janakiraman M; Linkesch W; Auner HW; Emberger W; Windpassinger C; Schimek MG; Hoefler G; Troppmair J; Sill H
    Cancer Res; 2006 Apr; 66(7):3401-8. PubMed ID: 16585161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination therapy targeting Raf-1 and MEK causes apoptosis of HCT116 colon cancer cells.
    Subramanian RR; Yamakawa A
    Int J Oncol; 2012 Nov; 41(5):1855-62. PubMed ID: 22922669
    [TBL] [Abstract][Full Text] [Related]  

  • 28. B-Raf inhibitors induce epithelial differentiation in BRAF-mutant colorectal cancer cells.
    Herr R; Köhler M; Andrlová H; Weinberg F; Möller Y; Halbach S; Lutz L; Mastroianni J; Klose M; Bittermann N; Kowar S; Zeiser R; Olayioye MA; Lassmann S; Busch H; Boerries M; Brummer T
    Cancer Res; 2015 Jan; 75(1):216-29. PubMed ID: 25381152
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery and optimization of N-acyl and N-aroylpyrazolines as B-Raf kinase inhibitors.
    Blackburn C; Duffey MO; Gould AE; Kulkarni B; Liu JX; Menon S; Nagayoshi M; Vos TJ; Williams J
    Bioorg Med Chem Lett; 2010 Aug; 20(16):4795-9. PubMed ID: 20630752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. B-Raf and C-Raf are required for Ras-stimulated p42 MAP kinase activation in Xenopus egg extracts.
    Yue J; Xiong W; Ferrell JE
    Oncogene; 2006 Jun; 25(23):3307-15. PubMed ID: 16434971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885.
    King AJ; Patrick DR; Batorsky RS; Ho ML; Do HT; Zhang SY; Kumar R; Rusnak DW; Takle AK; Wilson DM; Hugger E; Wang L; Karreth F; Lougheed JC; Lee J; Chau D; Stout TJ; May EW; Rominger CM; Schaber MD; Luo L; Lakdawala AS; Adams JL; Contractor RG; Smalley KS; Herlyn M; Morrissey MM; Tuveson DA; Huang PS
    Cancer Res; 2006 Dec; 66(23):11100-5. PubMed ID: 17145850
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition.
    Jin T; Lavoie H; Sahmi M; David M; Hilt C; Hammell A; Therrien M
    Nat Commun; 2017 Oct; 8(1):1211. PubMed ID: 29084939
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of Inactive Conformation-Selective Kinase Inhibitors by Utilizing Cascade Assays.
    Wang W; Krosky D; Ahn K
    Biochemistry; 2017 Aug; 56(34):4449-4456. PubMed ID: 28574701
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of a widespread cancer-causing mutation on the inactive to active dynamics of the B-Raf kinase.
    Marino KA; Sutto L; Gervasio FL
    J Am Chem Soc; 2015 Apr; 137(16):5280-3. PubMed ID: 25868080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis, in vitro antiproliferative evaluation, and kinase inhibitory effects of a new series of imidazo[2,1-b]thiazole derivatives.
    Abdel-Maksoud MS; Kim MR; El-Gamal MI; Gamal El-Din MM; Tae J; Choi HS; Lee KT; Yoo KH; Oh CH
    Eur J Med Chem; 2015 May; 95():453-63. PubMed ID: 25841200
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel inhibitors of the v-raf murine sarcoma viral oncogene homologue B1 (BRAF) based on a 2,6-disubstituted pyrazine scaffold.
    Niculescu-Duvaz I; Roman E; Whittaker SR; Friedlos F; Kirk R; Scanlon IJ; Davies LC; Niculescu-Duvaz D; Marais R; Springer CJ
    J Med Chem; 2008 Jun; 51(11):3261-74. PubMed ID: 18473434
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells.
    Salerno P; De Falco V; Tamburrino A; Nappi TC; Vecchio G; Schweppe RE; Bollag G; Santoro M; Salvatore G
    J Clin Endocrinol Metab; 2010 Jan; 95(1):450-5. PubMed ID: 19880792
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacophore and binding analysis of known and novel B-RAF kinase inhibitors.
    Baska F; Szabadkai I; Sipos A; Breza N; Szántai-Kis C; Kékesi L; Garamvölgyi R; Nemes Z; Baska F; Neumann L; Torka R; Ullrich A; Kéri G; Orfi L
    Curr Med Chem; 2014 Jun; 21(17):1938-55. PubMed ID: 24606495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The mechanism of activation of MEK1 by B-Raf and KSR1.
    Maloney RC; Zhang M; Liu Y; Jang H; Nussinov R
    Cell Mol Life Sci; 2022 May; 79(5):281. PubMed ID: 35508574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Purinylpyridinylamino-based DFG-in/αC-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profiling.
    Liu L; Lee MR; Kim JL; Whittington DA; Bregman H; Hua Z; Lewis RT; Martin MW; Nishimura N; Potashman M; Yang K; Yi S; Vaida KR; Epstein LF; Babij C; Fernando M; Carnahan J; Norman MH
    Bioorg Med Chem; 2016 May; 24(10):2215-34. PubMed ID: 27085672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.